• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.

作者信息

Moran Teresa, Sequist Lecia V

机构信息

Catalan Institute of Oncology, Hospital Germans Trias i Pujol and Universitat Autonoma de Barcelona, Barcelona, Spain.

出版信息

J Clin Oncol. 2012 Sep 20;30(27):3330-6. doi: 10.1200/JCO.2012.43.1858. Epub 2012 Jul 2.

DOI:10.1200/JCO.2012.43.1858
PMID:22753908
Abstract
摘要

相似文献

1
Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体（EGFR）突变肺癌患者的时机
J Clin Oncol. 2012 Sep 20;30(27):3330-6. doi: 10.1200/JCO.2012.43.1858. Epub 2012 Jul 2.
2
Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.肺癌中的表皮生长因子受体（EGFR）信号传导与EGFR共价抑制
J Clin Oncol. 2012 Sep 20;30(27):3417-20. doi: 10.1200/JCO.2012.43.1825. Epub 2012 Aug 20.
3
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.肝细胞生长因子降低了 EGFR-T790M 突变型肺癌对不可逆表皮生长因子受体抑制剂的敏感性。
Clin Cancer Res. 2010 Jan 1;16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204. Epub 2009 Dec 15.
4
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.表皮生长因子受体（EGFR）突变型肺癌对不可逆表皮生长因子受体抑制剂产生耐药性，揭示了新的治疗策略。
Cancer Res. 2007 Nov 1;67(21):10417-27. doi: 10.1158/0008-5472.CAN-07-1248.
5
Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
Br J Dermatol. 2006 Jul;155(1):213-4. doi: 10.1111/j.1365-2133.2006.07299.x.
6
EGFR inhibitors: what have we learned from the treatment of lung cancer?表皮生长因子受体抑制剂：我们从肺癌治疗中学到了什么？
Nat Clin Pract Oncol. 2005 Nov;2(11):554-61. doi: 10.1038/ncponc0341.
7
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.表皮生长因子受体酪氨酸激酶结构域突变对接受表皮生长因子受体酪氨酸激酶抑制剂治疗的非小细胞肺癌患者预后的影响。
Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. doi: 10.1158/1078-0432.CCR-06-0555.
8
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.非小细胞肺癌中 EGFR 突变和 ALK 易位对酪氨酸激酶抑制剂的敏感性差异。
Lung Cancer. 2012 Aug;77(2):460-3. doi: 10.1016/j.lungcan.2012.04.012. Epub 2012 May 21.
9
Combined targeted therapies in non-small cell lung cancer: a winner strategy?非小细胞肺癌的联合靶向治疗：一种成功策略？
Curr Opin Oncol. 2007 Mar;19(2):98-102. doi: 10.1097/CCO.0b013e328011beec.
10
Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.血清肝细胞生长因子对非小细胞肺腺癌患者表皮生长因子受体酪氨酸激酶抑制剂治疗反应的影响。
Clin Cancer Res. 2010 Sep 15;16(18):4616-24. doi: 10.1158/1078-0432.CCR-10-0383. Epub 2010 Aug 2.

引用本文的文献

1
Phylogenetic analysis and detection of positive selection in the SIRT gene family across vertebrates.脊椎动物SIRT基因家族的系统发育分析及正选择检测
Sci Rep. 2025 Jan 5;15(1):848. doi: 10.1038/s41598-025-85344-0.
2
Tyrosine Kinase Receptors in Oncology.肿瘤学中的酪氨酸激酶受体。
Int J Mol Sci. 2020 Nov 12;21(22):8529. doi: 10.3390/ijms21228529.
3
Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.表皮生长因子受体特异性免疫疗法的进展：从武装抗体中吸取的经验教训。
Oncotarget. 2020 Sep 22;11(38):3531-3557. doi: 10.18632/oncotarget.27730.
4
Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.开发一种新型针对 EGFR 的抗体药物偶联物用于胰腺癌治疗。
Target Oncol. 2019 Feb;14(1):93-105. doi: 10.1007/s11523-018-0616-8.
5
Co-occurrence of EGFR sensitising and resistance mutations at diagnosis in NSCLC.
Ir J Med Sci. 2019 May;188(2):405-408. doi: 10.1007/s11845-018-1868-0. Epub 2018 Jul 20.
6
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.既往表皮生长因子受体酪氨酸激酶抑制剂治疗进展后的表皮生长因子受体突变阳性非小细胞肺癌患者的临床管理：重复分子分析的必要性
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S21-S34. doi: 10.21037/tlcr.2017.10.03.
7
Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy.吉非替尼常导致先前接受过化疗的肺腺癌患者出现肝损伤。
Lung Cancer (Auckl). 2013 Jun 8;4:9-14. doi: 10.2147/LCTT.S45172. eCollection 2013.
8
miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.微小RNA-26a通过靶向蛋白酪氨酸磷酸酶非受体型13使非小细胞肺癌细胞对酪氨酸激酶抑制剂产生脱敏作用。
Oncotarget. 2016 Jul 19;7(29):45687-45701. doi: 10.18632/oncotarget.9920.
9
Cutaneous metastasis: a rare herald of a silent cancer.皮肤转移：一种罕见的隐匿性癌症先兆。
BMJ Case Rep. 2016 Jan 18;2016:bcr2015213734. doi: 10.1136/bcr-2015-213734.
10
Irreversible EGFR-TKIs: dreaming perfection.不可逆的 EGFR-TKIs：追求完美的梦想。
Transl Lung Cancer Res. 2013 Feb;2(1):40-9. doi: 10.3978/j.issn.2218-6751.2012.12.05.